000			03956nam a22003615i 4500
999			_c76011 _d76011 _x1
001			76011
003			ES-MaUEC
005			20230207040205.0
007			cr nn 008mamaa
008			130913s2013 xxu| s |||| 0|eng d
020			_a9781461479536
024	7		_a10.1007/978-1-4614-7953-6 _2doi
040			_beng
050		4	_aRC377 _b.M85 2013 EB
082	0	4	_a616.079
245	0	0	_aMultiple Sclerosis Immunology : _bA Foundation for Current and Future Treatments _cedited by Takashi Yamamura, Bruno Gran
260			_aNew York _bSpringer International Publishing _c2013
300			_a1 recurso en línea (XVII, 461 p.) _b46 ilustraciones, 38 ilustraciones en color
336			_aTexto (visual) _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
505	0		_aTh17 cells in autoimmune inflammation and demyelination in the central nervous system -- Regulatory T cells in MS -- T-bet: A critical regulator of encephalitogenic T Cells -- Antigen-presenting cells in the Central Nervous System -- The role of B cells in multiple sclerosis -- Diet, gut flora and multiple sclerosis: current research and future perspectives -- GM-CSF in autoimmune inflammation of the central nervous system -- The role of Toll-like receptors in multiple sclerosis and experimental autoimmune encephalomyelitis -- Macrophages and microglia in experimental autoimmune encephalomyelitis and multiple sclerosis -- Genetics of multiple sclerosis -- Gene expression profiling and pathway analysis for identification of molecular targets in MS -- Systems biology for the study of multiple sclerosis -- Checkpoints in the development of pathogenic and regulatory T cells in Experimental Autoimmune Encephalomyelitisâ€{u1822}asis for current future interventions in MS -- Modeling MS in non-human primates -- A novel concept of treatment in MS: targeting both oligodendrocyte death and inflammatory processes by inhibiting poly (ADP-Ribose) polymerase -- Association of MS with other autoimmune diseases -- Current and future treatments of Multiple Sclerosis -- Targeting CD52 for the treatment of Multiple Sclerosis -- Haematopoietic stem cells for the treatment of MS -- Mesenchymal stem cells for the treatment of Multiple Sclerosis
520			_aThe availability of powerful genome-wide association study technology, during the last five years, has shown that most of the znewy MS susceptibility loci are immune-response genes. It is clear that there is much novelty in the field of MS immunology, which has served as an impetus to invest in new therapies. Notably, most if not all of these are immunotherapies. Even the equally exciting field of cell-based therapies and neuro-regeneration may well rely on cells or growth factors that are no less immunomodulators than restorative of myelin and neural cell function. Multiple Sclerosis Immunology looks at MS immunology as the basis for the present and{u2014}even more{u2014}the future of treatments for this complex autoimmune condition. Both editors are immunologists, as well as clinical neurologists, and appreciate the importance of a sustained dialogue between basic and clinical scientists to ensure that ztranslationy is real and not just virtual
650		7	_aEsclerosis múltiple _0comprobar BNE19901007750 _2embne _9142007
700	1		_aYamamura, Takashi _eeditor literario _0Local _984808
700	1		_aGran, Bruno _eeditor literario _984809 _0Local
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-1-4614-7953-6 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
907			_a.b12816292 _b10-10-17 _c01-10-14
942			_2lcc _cLE
945			_aRC377 .M85 2013 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11545677 _z06-04-17
988			_aEBOOK, EBSPRINGERrevisado
998			_am _a_alco _a_vill _b04-04-17 _cm _dz _eu _feng _gxxu _h0